DHFR

Lysine-methotrexate is a dihydrofolate reductase (DHFR) inhibitor, structurally related to Methotrexate. This compound exhibits potent biological activity by inhibiting folate metabolism, making it useful in studying cellular processes that rely on nucleotide synthesis. Lysine-methotrexate is applicable in cancer research and other therapeutic contexts where modulation of DHFR activity is of interest.

DHFR-IN-2 is a potent uncompetitive inhibitor of MtDHFR (dihydrofolate reductase from Mycobacterium tuberculosis), demonstrating an IC50 value of 7 μM. This compound serves as a valuable tool for tuberculosis research, aiding in the study of pathogenic processes and potential therapeutic strategies against TB.

Denopterin is a dihydrofolate reductase (DHFR) inhibitor and an established antifolate agent. This compound functions as an antimetabolite, exhibiting cytotoxic effects on rapidly dividing cells, making it relevant for cancer research. Its ability to inhibit DHFR provides a valuable tool for investigating folate metabolism and developing therapeutic strategies against various malignancies.

TNP-351 is a dihydrofolate reductase (DHFR) inhibitor known for its potent antitumor activity. This antifolate compound exhibits efficacy against both leukemia and solid tumor cells in vitro and in vivo, making it a valuable tool in cancer research. Its mechanism of action involves the disruption of folate metabolism, ultimately hindering DNA synthesis and cell proliferation.

Aditoprime is a selective inhibitor of bacterial dihydrofolate reductase (DHFR), demonstrating IC50 values of 47 nM and 520 nM for E. coli and L. casei DHFR, respectively. By inhibiting the conversion of dihydrofolic acid to tetrahydrofolic acid, Aditoprime effectively impairs bacterial folate synthesis. This compound exhibits broad-spectrum antibacterial activity and possesses favorable pharmacokinetic properties, making it a useful reagent in microbiological research and antibiotic development studies.

PROTAC eDHFR Degrader-1 is a proteolysis-targeting chimera (PROTAC) that specifically targets eDHFR for ubiquitin-mediated degradation. This compound effectively degrades eDHFR-YFP and various protein of interest (POI), including yellow fluorescent protein (YFP) and luciferase. Its application in research can facilitate the study of protein function and dynamics through targeted protein degradation, providing insights into cellular processes and potential therapeutic pathways.

Proguanil is a potent dihydrofolate reductase (DHFR) inhibitor, primarily utilized in antimalarial research. Upon administration, it is metabolized to Cycloguanil, its active form, enhancing its efficacy against Plasmodium species. This compound is essential for studying the biochemical pathways of folate metabolism and developing therapeutic strategies against malaria.